MinuteCE®
A robust collection of short-form, digestible CE activities that are made to fit into any schedule. With MinuteCE, you’re in control of the content you want, when you want it. To start microlearning, follow these simple steps:
Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
Why choose microlearning?
- Bite-sized episodes
- The most relevant content
- Improved retention
To experience MinuteCE for yourself, select one of the episodes below to start learning!
Episodes 361-375 of 400
Examining the Lifetime Impact of a 25-Year Misdiagnosis – Part 1
MinuteCE®Examining the Lifetime Impact of a 25-Year Misdiagnosis – Part 1
Examining the Lifetime Impact of a 25-Year Misdiagnosis – Part 2
MinuteCE®Examining the Lifetime Impact of a 25-Year Misdiagnosis – Part 2
- advertisement
IBD & The Evolution of Targeted Therapies – How Far Have We Come?
MinuteCE®IBD & The Evolution of Targeted Therapies – How Far Have We Come?
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
MinuteCE®What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
MinuteCE®Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
MinuteCE®Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
- advertisement
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
MinuteCE®Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
MinuteCE®What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
MinuteCE®How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
